At a Glance
- Companies: CytoReason; Sanofi
- Location: Tel Aviv, Israel (CytoReason); Paris, France (Sanofi)
- Deal value: Up to US$16 million in funding
- Focus area: AI‑powered disease modelling and target discovery in immunology
- Next steps: Deepen multi‑year collaboration across additional immunology programmes
What happened?
CytoReason has extended and expanded its multi‑year AI‑driven disease‑modelling collaboration with Sanofi, valued at up to US$16 million, marking the third expansion of the partnership. The agreement builds on prior phases focused on immunology target identification and validation using CytoReason’s platform.
Why does it matter?
Sanofi’s immunology portfolio, including Dupixent and emerging bispecifics, requires continuous innovation in target biology to sustain leadership amid competition from Regeneron, Roche and others. CytoReason’s Opal Computational Platform integrates multimodal data (genomics, transcriptomics, proteomics) with generative AI to model diseases at cellular resolution, accelerating hypothesis generation and reducing failure rates in complex immune pathways.
Who’s behind it?
CytoReason is an Israel‑based clinical‑stage AI biotech using proprietary models trained on vast human disease datasets to predict therapeutic responses and nominate targets. Sanofi is a global immunology leader expanding computational partnerships to enhance R&D efficiency.
How was it achieved?
The expansion provides additional funding for CytoReason to apply its platform to more Sanofi immunology projects, generating prioritised targets and biomarkers for validation. Sanofi retains rights to resulting discoveries, with CytoReason eligible for downstream milestones and royalties.
What’s next?
The partners will prioritise high‑confidence targets for preclinical advancement, potentially feeding into Sanofi’s phase 1 pipeline. This deepens a model where repeated expansions validate AI’s role in derisking early discovery.
What are people saying?
CytoReason CEO Yohay Kaplan called it a “testament to the transformative impact” of their platform on Sanofi’s immunology efforts. Sanofi R&D leaders highlighted the value of AI‑human disease models for “unlocking new biology”.